Palvella Therapeutics (PVLA) Free Cash Flow Growth (5y) (2018 - 2026)

Palvella Therapeutics (PVLA) Free Cash Flow Growth (5y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Palvella Therapeutics 1.88 Bn 1.61 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 2.17%
Dec 31, 2025 18.91%
Sep 30, 2025 -3.26%
Jun 30, 2025 12.90%
Mar 31, 2025 16.88%
Dec 31, 2024 18.66%
Sep 30, 2024 26.62%
Jun 30, 2024 32.76%
Mar 31, 2024 40.86%
Dec 31, 2023 32.77%
Sep 30, 2023 7.78%
Jun 30, 2023 -7.55%
Mar 31, 2023 -18.71%
Dec 31, 2022 -20.39%
Sep 30, 2022 -17.33%
Jun 30, 2022 -17.67%
Mar 31, 2022 -23.73%
Dec 31, 2021 -10.13%
Sep 30, 2021 -31.49%
Jun 30, 2021 46.78%